Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT 05280314 Brief Summary This is a multicenter, multi-arm trial evaluating…
Read more arrow_forwardNCT 05280314 Brief Summary This is a multicenter, multi-arm trial evaluating…
Read more arrow_forwardNCT 04925648 Brief Summary The study’s purpose is to understand the appearance…
Read more arrow_forwardNCT 05870748 Brief Summary A Phase 2/3 study to investigate the…
Read more arrow_forwardNCT 05862051 Brief Summary This study aims to assess the clinical…
Read more arrow_forwardNCT 06109779 Brief Summary A global study to assess the efficacy…
Read more arrow_forwardNCT 06170788 Brief Summary The primary objective of the study is to…
Read more arrow_forwardNCT 06132958 Brief Summary Researchers are looking for new ways to treat…
Read more arrow_forwardNCT 06074588 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 06074588 Brief Summary The purpose of this study is to evaluate…
Read more arrow_forwardNCT 04262466 Brief Summary Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell…
Read more arrow_forward